Reino Unido - inglês - MHRA (Medicines & Healthcare Products Regulatory Agency)

bowmed ibisqus ltd - ceftazidime pentahydrate - powder for solution for injection - 1gram

Reino Unido - inglês - MHRA (Medicines & Healthcare Products Regulatory Agency)

bowmed ibisqus ltd - ceftazidime pentahydrate - powder for solution for injection - 2gram

União Europeia - inglês - EMA (European Medicines Agency)

pfizer ireland pharmaceuticals - avibactam sodium, ceftazidime pentahydrate - pneumonia, bacterial; soft tissue infections; pneumonia; urinary tract infections; gram-negative bacterial infections - antibacterials for systemic use, - zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:complicated intra-abdominal infection (ciai)complicated urinary tract infection (cuti), including pyelonephritishospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap)treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.zavicefta is also indicated for the treatment of infections due to aerobic gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options.consideration should be given to official guidance on the appropriate use of antibacterial agents.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ceftazidime pentahydrate -

Malta - inglês - Malta Medicines Authority

wockhardt uk limited ash road north, wrexham, ll13 9uf, united kingdom - ceftazidime pentahydrate - powder for solution for injection - ceftazidime pentahydrate 1 g - antibacterials for systemic use

Malta - inglês - Malta Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - ceftazidime pentahydrate - powder for solution for infusion or injection - ceftazidime pentahydrate 1 g - antibacterials for systemic use

Malta - inglês - Malta Medicines Authority

stravencon limited - ceftazidime pentahydrate - powder for solution for infusion or injection - ceftazidime pentahydrate 1161.44 mg - antibacterials for systemic use

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - ceftazidime pentahydrate 1.1648 g equivalent to ceftazidime 1 g (sterile);   - powder for injection - 1 g - active: ceftazidime pentahydrate 1.1648 g equivalent to ceftazidime 1 g (sterile)   excipient: sodium carbonate - indicated for the treatment of adults and children including neonates with single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other beta-lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available (see section 5.1 pharmacodynamic properties). indications include: - severe infections e.g. - septicaemia, bacteraemia, peritonitis, meningitis. - infections in immunosuppressed patients. - infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary and abdominal infections. - bone and joint infections. - infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd).

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - ceftazidime pentahydrate 2.3296 g equivalent to ceftazidime 2 g (sterile);   - powder for injection - 2 g - active: ceftazidime pentahydrate 2.3296 g equivalent to ceftazidime 2 g (sterile)   excipient: sodium carbonate - indicated for the treatment of adults and children including neonates with single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other beta-lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available (see section 5.1 pharmacodynamic properties). indications include: - severe infections e.g. - septicaemia, bacteraemia, peritonitis, meningitis. - infections in immunosuppressed patients. - infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary and abdominal infections. - bone and joint infections. - infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd).

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - ceftazidime pentahydrate 1.16 g equivalent to ceftazidime 1g - powder for injection - 1 g - active: ceftazidime pentahydrate 1.16 g equivalent to ceftazidime 1g excipient: sodium carbonate - indicated for the treatment of adults and children including neonates with single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other beta-lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available. indications include: - severe infections: for example: · septicaemia, bacteraemia, peritonitis, meningitis. · infections in immunosuppressed patients. · infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary, and abdominal infections. - bone and joint infections. - infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd)